Figure 4
In vivo inhibition of IL-4 secretion during NS-398 treatment. Antibody-treated mice received 1 mg of anti-IL-4 mAb (11B11) or control mAb (GL113) in 200 ml of saline i.p. Starting the next day, mice were injected with NS-398 during OVA treatment, sensitized, and challenged as described in Figure 1. *Statistically significant (P<0.01). IL, interleukin; mAb, monoclonal antibody; i.p. intraperitoneal; OVA, ovalbumin.
